Allegro, Hanmi enter license agreement for Luminate in Korea, China

Allegro Ophthalmics and Hanmi Pharmaceutical have entered into a license agreement for Luminate in the Republic of Korea and the People’s Republic of China, according to a press release from Allegro.Under the license agreement, Hanmi will pay Allegro upfront licensing fees, sales milestone payments and running royalties as a percentage of net sales. Hanmi will also make a $20 million strategic investment in Allegro, the release said.

Clinical features differentiate retinoblastoma, Coats’ disease

BOSTON — Physicians can distinguish between Coats’ disease and retinoblastoma in the clinic if they know what features to look for, according to one expert.“You have to look at the pupillary reflex, the appearance of the anterior chamber, the clarity of the vitreous, the color of the subretinal fluid, the caliber and course of the retinal vessels, and the macular appearance,”Jerry A. Shields, MD, told colleagues at Macula 2015.